A. SREENIVASA REDDY (ABU DHABI)
Abu Dhabi-headquartered Arcera Life Sciences has secured an exclusive licence to commercialise a new drug for treating type 2 diabetes, with clinical studies also showing promising results in weight reduction among people with overweight or obesity.
Arcera signed a licensing and commercialisation agreement with Hong Kong-listed Innogen Pharmaceuticals, a Shanghai-based biopharmaceutical company, for Efsubaglutide Alfa, a GLP-1 receptor agonist therapy, covering several international markets, including the UAE.
Under the agreement, Arcera will be responsible for regulatory activities, market access and commercialisation of the treatment in selected countries across Africa, Eastern Europe, Latin America, and the Middle East, the companies said in a joint statement.
The agreement strengthens Arcera's portfolio of medicines for cardiometabolic diseases, including diabetes and obesity, while supporting Innogen's expansion into international markets.
Efsubaglutide Alfa is a next-generation, ultra-long-acting GLP-1 receptor agonist developed by Innogen. The drug has already been approved for treating type 2 diabetes in mainland China and Macao, and has been included in China's National Reimbursement Drug List.
Clinical studies showed that the treatment reduced HbA1c, a measure of average blood sugar levels, by approximately 2.2 percentage points after 24 weeks.
In clinical studies involving Chinese adults with overweight or obesity, 18 weeks of treatment resulted in average weight reductions of 10.6% with once-weekly dosing and 9.7% when administered once every two weeks.
The studies also reported improvements in body composition, with the muscle-to-fat ratio increasing by up to 45.3% from baseline among participants receiving weekly doses. Liver fat content declined by up to 51.8% in the same dosing group.
According to the statement, the treatment was generally well tolerated, with no participants discontinuing treatment because of adverse events during the 18-week study period. The reported incidence of gastrointestinal adverse events was low relative to other GLP-1 therapies based on comparisons across clinical trials.
Innogen has also completed a Phase II clinical trial in Australia evaluating the efficacy and safety of once-monthly dosing in adults with overweight or obesity. The findings are expected to support future regulatory registration and commercialisation efforts.
Isabel Afonso, Chief Executive Officer of Arcera Life Sciences, said the agreement would expand access to innovative treatments for chronic diseases across the company's international markets.
“Cardiometabolic diseases remain among the most pressing healthcare challenges in the markets we serve. Our agreement with Innogen accelerates the bridge we are building between China and our international markets to bring innovative medicines to more patients and strengthen our cardiometabolic portfolio,” Afonso said.
“By combining our partners’ scientific capabilities with Arcera’s regulatory expertise, market access and overall commercial reach, we aim to turn innovation into meaningful impact for people living with chronic disease.”
According to the International Diabetes Federation, 589 million adults worldwide are living with diabetes, a figure projected to reach 853 million by 2050, the statement said.
GLP-1 receptor agonists are used in managing type 2 diabetes and increasingly obesity. In 2025, the World Health Organisation added GLP-1 therapies to its Model List of Essential Medicines and issued global guidelines on their use in treating obesity, which affects more than one billion people worldwide.
Dr Qinghua Wang, Founder, Chairman and Chief Executive Officer of Innogen Pharmaceuticals, said the collaboration represented an important step in the company's international expansion.
“Innogen’s mission is to provide best-in-class and first-in-class therapies for people living with diabetes, obesity and other metabolic diseases worldwide. Our collaboration with Arcera is an important step toward this vision,” Wang said.
“By combining Innogen’s scientific innovation with Arcera’s strengths in international regulatory affairs and commercialisation, we aim to broaden access to differentiated therapies and ultimately improve the quality of life of patients around the world.”
Innogen said in a separate filing with the Hong Kong Stock Exchange that the total potential value of the licensing agreement exceeds $1 billion.
According to the stock exchange disclosure, the agreement has an initial term of 15 years and provides for upfront and near-term milestone payments of up to $38 million, including a non-refundable upfront payment of $15 million.
Innogen will also be entitled to additional payments linked to sales milestones and tiered royalties of up to double-digit percentage rates based on annual net sales of the drug in the licensed territories.
The agreement grants Arcera exclusive rights to develop the drug to the extent necessary to obtain and maintain regulatory approvals, and to commercialise it within the agreed markets.
The companies said commercialisation would begin after the necessary local regulatory approvals and other applicable requirements had been met.